Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (101-110 of 272) with videos related to

Pageof 28
Sort By:
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|November 25, 2014
Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: results of an international surveyDésirée van der Heijde, Joachim Sieper, Dirk Elewaut, et al.
Annals of the Rheumatic Diseases|October 21, 2011
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE studyJürgen Braun, Atul Deodhar, Robert D Inman, et al.
Rheumatology and Therapy|November 2, 2019
Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the GapAtul Deodhar, Lianne S Gensler, Marina Magrey, et al.
Rheumatology (Oxford, England)|December 28, 2018
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 studyJürgen Braun, Xenofon Baraliakos, Atul Deodhar, et al.
RMD Open|September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitorsPeter Nash, Frank Behrens, Ana-Maria Orbai, et al.
Frontiers in Immunology|December 16, 2020
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1Jui-Cheng Tseng, James Cheng-Chung Wei, Atul Deodhar, et al.
Rheumatology and Therapy|September 25, 2024
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical TrialsPhilip Mease, Tatiana Korotaeva, Pavel Shesternya, et al.
Rheumatology (Oxford, England)|November 10, 2023
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysisAtul Deodhar, Pedro M Machado, Michael Mørup, et al.
Arthritis Care & Research|November 1, 2023
Relationships of Work Productivity and Activity Impairment With Patient-Reported Outcomes in Ankylosing Spondylitis: Results From Two TrialsMarina Magrey, James Cheng-Chung Wei, Arne Yndestad, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 28, 2016
Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back PainAtul Deodhar, Philip J Mease, John D Reveille, et al.
Pageof 28

Showing results (101-110 of 272) with videos related to

Sort By:
Pageof 28
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|November 25, 2014
Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: results of an international surveyDésirée van der Heijde, Joachim Sieper, Dirk Elewaut, et al.
Annals of the Rheumatic Diseases|October 21, 2011
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE studyJürgen Braun, Atul Deodhar, Robert D Inman, et al.
Rheumatology and Therapy|November 2, 2019
Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the GapAtul Deodhar, Lianne S Gensler, Marina Magrey, et al.
Rheumatology (Oxford, England)|December 28, 2018
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 studyJürgen Braun, Xenofon Baraliakos, Atul Deodhar, et al.
RMD Open|September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitorsPeter Nash, Frank Behrens, Ana-Maria Orbai, et al.
Frontiers in Immunology|December 16, 2020
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1Jui-Cheng Tseng, James Cheng-Chung Wei, Atul Deodhar, et al.
Rheumatology and Therapy|September 25, 2024
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical TrialsPhilip Mease, Tatiana Korotaeva, Pavel Shesternya, et al.
Rheumatology (Oxford, England)|November 10, 2023
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysisAtul Deodhar, Pedro M Machado, Michael Mørup, et al.
Arthritis Care & Research|November 1, 2023
Relationships of Work Productivity and Activity Impairment With Patient-Reported Outcomes in Ankylosing Spondylitis: Results From Two TrialsMarina Magrey, James Cheng-Chung Wei, Arne Yndestad, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 28, 2016
Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back PainAtul Deodhar, Philip J Mease, John D Reveille, et al.
Pageof 28